In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Myomatrix Therapeutics LLC

Latest From Myomatrix Therapeutics LLC

Start-Up Previews (4/03)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Orphan Drugs, features profiles of Amicus Therapeutics Inc., Myomatrix Therapeutics LLC and Vipogen LLC. Plus these Start-Ups across Health Care: Advagen Inc., Aviva Biosciences Corp., Gene Network Sciences Inc., Hypnion Inc. and Savacor Inc.

Myomatrix Therapeutics LLC

Myomatrix is the creation of a heart transplant cardiologist with a mission of preventing his patients from developing transplant vasculopathy, the most common cause of late heart graft loss a year or more after a heart transplant operation. But the start-up's kinase inhibitors have application to much larger diseases as well, including congestive heart failure and angina.

BioPharmaceutical Platform Technologies

Start-ups Pursuing Orphan Drug Indications

Now 20 years old, the Orphan Drug Act still provides an attractive development option for industry, as typified by the start-ups profiled in this issue.

Business Strategies Regulation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics